Wire · opportunities
US FDA approves Regeneron's rare bone disorder drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
The US FDA approved Regeneron's drug garetosmab (Pasatru) for fibrodysplasia ossificans progressiva, a rare bone disorder, after it significantly reduced abnormal bone formation in clinical trials.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
Regeneron’s FDA approval opens a rare disease treatment market that quickly needs clinical follow-ups and paediatric trials. You should evaluate patient access and positioning ahead of competitor therapies like Ipsen's Sohonos.
◆ Coverage
8 sources · first reported 19 Aug 2026 · latest 31 Aug 2026
◆ Topics